Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced endometrial cancer : a southwest oncology group study

Nineteen evaluable patients with advanced endometrial cancer refractory to one prior chemotherapeutic regimen were treated with a 5-day schedule of fludarabine phosphate. No responses were noted. The major toxicity was grade 2 or greater leukopenia in 45% of patients. Fludarabine phosphate at this d...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of clinical oncology 1991-06, Vol.14 (3), p.193-194
Hauptverfasser:	VON HOFF, D. D, GREEN, S, ALBERTS, D. S, STOCK-NOVACK, D. L, SURWIT, E. A, MILLER, T. P, STEPHENS, R. L
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antimetabolites, Antineoplastic - adverse effects Antimetabolites, Antineoplastic - therapeutic use Antineoplastic agents Biological and medical sciences Chemotherapy Drug Administration Schedule Drug Evaluation Female Hematologic Diseases - chemically induced Humans Medical sciences Middle Aged Pharmacology. Drug treatments Uterine Neoplasms - drug therapy Vidarabine Phosphate - adverse effects Vidarabine Phosphate - analogs & derivatives Vidarabine Phosphate - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Nineteen evaluable patients with advanced endometrial cancer refractory to one prior chemotherapeutic regimen were treated with a 5-day schedule of fludarabine phosphate. No responses were noted. The major toxicity was grade 2 or greater leukopenia in 45% of patients. Fludarabine phosphate at this dose and schedule does not appear to be an active agent for patients with refractory endometrial cancer.
ISSN:	0277-3732 1537-453X
DOI:	10.1097/00000421-199106000-00004